These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 22910842)

  • 1. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings.
    Cavaletti G; Cornblath DR; Merkies ISJ; Postma TJ; Rossi E; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; ; Mazzeo A; Pace A; Pessino A; Schenone A; Toscano A; Argyriou AA; Brouwer B; Frigeni B; Piras B; Briani C; Dalla Torre C; Dominguez Gonzalez C; Faber CG; Tomasello C; Binda D; Brandsma D; Cortinovis D; Psimaras D; Ricard D; Storey D; Cornblath DR; Galiè E; Lindeck Pozza E; Rossi E; Vanhoutte EK; Lanzani F; Pastorelli F; Altavilla G; Cavaletti G; Granata G; Kalofonos HP; Ghignotti I; Merkies ISJ; Bruna J; Hense J; Heimans JJ; Mattavelli L; Padua L; Reni L; Bakkers M; Boogerd M; Campagnolo M; Cazzaniga M; Eurelings M; Leandri M; Lucchetta M; Penas Prado M; Russo M; Valsecchi MG; Piatti ML; Alberti P; Bidoli P; Grant R; Plasmati R; Velasco R; Lalisang RI; Meijer RJ; Fabbri S; Dorsey SG; Galimberti S; Kerrigan S; Koeppen S; Postma TJ; Boogerd W; Grisold W
    Ann Oncol; 2013 Feb; 24(2):454-462. PubMed ID: 22910842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin.
    Alberti P; Rossi E; Cornblath DR; Merkies IS; Postma TJ; Frigeni B; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Faber CG; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Valsecchi MG; Cavaletti G;
    Ann Oncol; 2014 Jan; 25(1):257-64. PubMed ID: 24256846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
    Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
    Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability and Validity of the EORTC QLQ-CIPN20 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale) among Thai Women with Breast Cancer Undergoing Taxane-Based Chemotherapy.
    Rattanakrong N; Thipprasopchock S; Siriphorn A; Boonyong S
    Asian Pac J Cancer Prev; 2022 May; 23(5):1547-1553. PubMed ID: 35633537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.
    Lavoie Smith EM; Barton DL; Qin R; Steen PD; Aaronson NK; Loprinzi CL
    Qual Life Res; 2013 Dec; 22(10):2787-99. PubMed ID: 23543373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.
    Knoerl R; Gray E; Stricker C; Mitchell SA; Kippe K; Smith G; Dudley WN; Lavoie Smith EM
    Support Care Cancer; 2017 Nov; 25(11):3437-3446. PubMed ID: 28577231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.
    Li T; Timmins HC; Mahfouz FM; Trinh T; Mizrahi D; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Rutherford C; Goldstein D; Park SB
    JAMA Netw Open; 2024 Aug; 7(8):e2424139. PubMed ID: 39120903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to assess Chemotherapy-induced peripheral neuropathy.
    Kim HY; Kang JH; Youn HJ; So HS; Song CE; Chae SY; Jung SH; Kim SR; Kim JY
    J Korean Acad Nurs; 2014 Dec; 44(6):735-42. PubMed ID: 25608551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the reliability and validity of clinically-relevant outcome measures for chemotherapy-induced peripheral neuropathy.
    Knoerl R; Sohn MB; Spath K; Burnette B; Francar L; Mustian KM; Shah D; Gauthier L; Gewandter JS
    Support Care Cancer; 2024 Sep; 32(10):675. PubMed ID: 39297964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychometric Testing of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy 20-Item Scale Using Pooled Chemotherapy-Induced Peripheral Neuropathy Outcome Measures Standardization and Alliance for Clinical Trials in Oncology A151408 Study Data.
    Smith EML; Banerjee T; Yang JJ; Bridges CM; Alberti P; Sloan JA; Loprinzi C
    Cancer Nurs; 2019; 42(3):179-189. PubMed ID: 29649081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.
    Le-Rademacher J; Kanwar R; Seisler D; Pachman DR; Qin R; Abyzov A; Ruddy KJ; Banck MS; Lavoie Smith EM; Dorsey SG; Aaronson NK; Sloan J; Loprinzi CL; Beutler AS
    Support Care Cancer; 2017 Nov; 25(11):3537-3544. PubMed ID: 28634656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
    Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
    J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
    Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
    Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Content Validity of a Chemotherapy-Induced Peripheral Neuropathy Patient-Reported Outcome Measure.
    Lavoie Smith EM; Haupt R; Kelly JP; Lee D; Kanzawa-Lee G; Knoerl R; Bridges C; Alberti P; Prasertsri N; Donohoe C
    Oncol Nurs Forum; 2017 Sep; 44(5):580-588. PubMed ID: 28820525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials.
    Smith EML; Knoerl R; Yang JJ; Kanzawa-Lee G; Lee D; Bridges CM
    Cancer Control; 2018; 25(1):1073274818756608. PubMed ID: 29480026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Psychometric evaluation of the Arabic Version the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20).
    Abu Sharour L
    Appl Neuropsychol Adult; 2021; 28(5):614-618. PubMed ID: 31612735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-Induced Peripheral Neuropathy (CIPN) as a Predictor of Decreased Quality of Life in Testicular Germ Cell Tumor Survivors.
    Orszaghova Z; Galikova D; Lesko P; Obertova J; Rejlekova K; Sycova-Mila Z; Palacka P; Kalavska K; Svetlovska D; Mladosievicova B; Mardiak J; Mego M; Chovanec M
    Clin Genitourin Cancer; 2024 Jun; 22(3):102067. PubMed ID: 38555680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
    Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
    Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
    Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
    Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.